To study the pathogenicity of mouse cytomegalovirus (MCMV) and to identify virulence determinants, we have isolated and phenotypically characterised 25 temperature-sensitive (ts) mutants. Six of these (tsm9, tsml3, tsm20, tsm22, tsm28 and tsm30) failed to replicate in mice and were avirulent. Five mutants (tsml4, tsml8, tsml9, tsm25 and tsm27) were of similar virulence to the parental wild-type (wt) virus, five (tsm7, tsml5, tsm24, tsm26 and tsm31) were 12-100 fold less virulent, five (tsm8, tsml2, tsml6, tsm23 and tsm29) were 150-1500 fold less virulent and four (tsmlO, tsmll, tsml7 and tsm21) were between 2,000 and 85,000 fold less virulent than wt. One mutant (tsm28) did not plaque or replicate at 39°C while 5 other mutants (tsm7, tsm9, tsm23, tsm24 and tsm27) also failed to plaque at 39°C but only failed to replicate or replicated poorly at 40°C. A further two mutants (tsmlO and tsml3) were able to plaque and replicate at 39°C but not 40°C. Six other mutants (tsml4, tsml5, tsml6, tsm21, tsm22 and tsm30) failed to form plaques at 40°C and were severely restricted in their replication at 40°C. The remaining 11 mutants exhibited varying degrees of restriction in ability to plaque and/or replicate at non-permissive temperatures. These 25 mutants, together with 6 isolated previously, comprise at least 24 complementation groups.
Introduction
Human cytomegalovirus (HCMV) produces a wide spectrum of disease [1, 2] . The vast majority of cases are asymptomatic but result in latent infection. The most serious infections, which may 254 AIDS patients to control retinitis [9] . However, ganciclovir has proved toxic and at present is recommended for use only in sight-or life-threatening conditions. In addition, although the therapy initiates clinical improvement, ultimately all patients with proved CMV pneumonia succumb to the infection. Live vaccines are also being examined [10] but there is concern as to whether such viruses could become latent and, under adverse circumstances, be reactivated to cause disease. Thus, knowledge of the viral mechanisms and determinants involved in these conditions is urgently needed. These studies can best be carried out at the experimental level using suitable animal models.
Animal experiments cannot be accomplished with HCMV because of the strict species specificity of the cytomegaloviruses. Murine CMV (MCMV) in mice is a convenient virus-host model in which to study aspects of pathogenesis since subclinical and latent infections occur and the latter may be reactivated following various treatments [11] ; MCMV may also cause interstitial pneumonitis [12] . However, knowledge of the mechanisms and determinants involved, as with HCMV, is still largely lacking predominantly due to the absence of genetically stable virus strains of differing virulence for use in the murine model.
Recently we have described the isolation and preliminary characterisation of six temperaturesensitive (ts) mutants of MCMV derived by mutagenesis of virulent wild-type (wt) virus with Nmethyl-N-nitro-N-nitrosoguanidine (MNNG) [13] . These mutants varied in virulence from avirulent through 10-100 fold less virulent than wt virus and could be characterised into at least 4 complementation groups. However, the genomes of both HCMV and MCMV are large and it has been estimated that greater than 100 proteins can be encoded; indeed there are 208 open reading frames in HCMV but not all are expected to represent functional genes [14] . In addition, both HCMV and MCMV have been estimated to have at least 30 complementation groups [15] . Thus, the aim of the present study was to produce more ts mutants representing complementation groups and hence genetic mutations additional to those already described.
Materials and Methods

Animals
Mice used throughout this study were obtained from the animal breeding unit of the Biomedical Services Unit, Birmingham University.
Cells
Primary mouse embryo fibroblasts (MEFs) were prepared from the foetuses of 16-day pregnant CD1 mice as described previously [13] .
Viruses and their titration
Temperature-sensitive mutants PP31/15, PP99/3, PP242/68, PP268/38, PP269/38 and PP392/31 of MCMV and the parental wild-type (wt) virus have been described previously, as have the methods of preparation of virus stocks and their assay in mouse embryo fibroblast (MEF) cells at permissive (33°C) and non-permissive (39°C or 40°C) temperatures [13] . These mutants have been redesignated temperature-sensitive mutants (tsm) 1-6 respectively to facilitate a simpler classification of the total 31 mutants (see below).
Mutagenesis of wild-type virus
The procedure for mutagenesis of wt virus and isolation of ts mutants has been described previously [13] . Briefly, MEF ceils infected with mouse-passaged wt virus were treated with 10 /xg/ml MNNG 72 h post-infection (p.i.) and culture fluids harvested two days later. Temperature-sensitive mutants were isolated from the mutagenised virus stocks by 'picking' small plaques present after two days incubation at 33°C followed by temperature-shift to 39°C for four days. In each case the clone was grown up to produce a cloned stock and examined for ability to form plaques at 33°C, 39°C and 40°C. Viruses which showed little or no ability to form plaques at non-permissive (39°C or 40°C) temperatures were cloned again by the same procedure but without temperature-shift.
Complementation tests
Complementation by these mutants was assessed as described previously [13] . As some of a Virus stocks were grown at 33°C and then assayed at 33°C, 39°C and 40°C; b Infected cells were incubated for 6 days at 33°C, 39°C or 40°C and the resultant virus yields were determined at 33°C; c Mouse stocks were prepared by i.p. inoculation of CD1 mice with tissue culture grown virus (to produce mouse passage 1 stock) and salivary glands harvested 3 weeks after inoculation; mouse-passaged 1 stock was then used to inoculate mice similarly to produce mouse-passaged 2 stock. The stocks were assayed at 33°C, 39°C and 40°C; d Lethality determined by i.p. inoculation of 1-week-old BALB/c mice; e These mutants did not replicate in mice using the highest inoculum possible; mutants tsm9, tsm28 and tsrn30 did not replicate at first passage in mice, the remaining 3 mutants replicated poorly (2-4 × 102 pfu/ml) on first passage but not on second passage. 
Results
Isolation and growth characteristics of temperature-sensitiL,e mutants
Using the protocol described previously of treating virus-infected cells with 10 /,tg/ml of MNNG 72 h post-infection and harvesting the mutated viruses at 120 h post-infection, ts mutants were readily isolated. When small plaques were 'picked' using agar as the overlay and following temperature shift from 33°C to 39°C for four days incubation after two days incubation at 33°C, a total of 25 ts mutants were isolated from 180 picked plaques.
Analysis of cell grown working stocks showed that six mutants (tsm7, tsm9, tsm23, tsm24, tsm27 and tsm28) did not plaque at 39°C (Table 1) .
They were also considerably restricted in their replication at 39°C; yields were reduced by 25-to 3000-fold at 39°C compared with 33°C. Four of these six mutants failed to replicate at 40°C while the remaining two (tsm23 and tsm24) were severely restricted in their replication at this temperature (Table 1) . A further eight mutants (tsmlO, tsml3, tsm14, tsm15, tsm16, tsm21, tsrn22 and tsm30) were restricted (5-to 80-fold) in their ability to form plaques at 39°C but were unable to form plaques at 40°C. Two of these mutants (tsmlO and tsml3) failed also to replicate at 40°C while the remaining six were severely restricted (600-to 251,000-fold) in their replication at this temperature (Table 1) . Of the remaining eleven mutants, seven (tsmS, tsmll, tsm18, tsrn20, tsm26, tsm29 and tsm31) were 80-fold or greater restricted in their ability to form plaques at 40°C and replicated poorly at this temperature (Table   1) . Although mutants tsm12, tsm17, tsml9 and tsm25 were only poorly restricted (6-to 63-fold)
in their ability to form plaques at 40°C as judged by the data for tissue culture grown stocks in Table 1 , titration of other stocks including mouse grown stocks (see Table 1 ) confirmed that they were ts mutants and indeed they were restricted (100-to 126,000-fold) in their ability to replicate at 40°C (Table 1) suggesting that they may be defective in their release from cells at non-permissive temperatures.
Virulence to mice of wild-type and mutant t~iruses
The pfu/LDso of the parental and various mutant viruses grown as stocks by passage in mice (mouse passage 2) are shown in Table 1 . Mouse stocks were prepared by i.p. inoculation of 3-week-old CD-1 mice with non-passaged (to produce mouse passage 1) or mouse-passaged (to produce mouse passage 2) stocks, diluted (< 10-fold) or undiluted depending upon the titre or virulence of the stock. The LDs~ / of wt virus for 1-week-old BALB/c mice was 20 pfu in agreement with previously published data [13, 17] . Six mutants (tsm9, tsrnl3, tsm20, tsm22, tsm28 and tsm30) were avirulent; that is, attempts to produce mouse passaged virus were unsuccessful (Table 1) . Three of these mutants (tsm9, tsm28 and tsm30) did not replicate when inoculated into mice to produce mouse passage number 1; the other three mutants (tsml3, tsm20 and tsrn22) did produce stocks with low titres on first inoculation into mice but failed to replicate at the second passage.
Mutants that could be grown in mice showed considerable differences in virulence. Nine mutants (tsm7, tsm8, tsmlO, tsmll, tsml5, tsml6, tsml7, tsm21 and tsm23) did not kill mice at the highest inoculum available and, of these, six were > 500-fold less virulent than wt virus, two (tsm23 and tsm15) were between 100-and 180-fold less virulent and the remaining one (tsm7) ~ 18-fold less virulent. For those ten mutants where an accurate determination was possible, one mutant (tsml2) was ~ 2000-fold less virulent than parental wt virus, another (tsm29)was -350-fold less virulent, three (tsm24, tsm26 and tsm31)
were between 12-to 56-fold less virulent while the remaining five (tsrnl4, tsml8, tsrnl9, tsrn25 and tsm27) were < 10-fold less virulent (Table  1 ). All ts mutants were still ts in phenotype after two passages in mice although mouse-passage stock 2 of mutants tsrnl4, tsml9 and tsrn24 with virulence determinations similar to wt virus have ts phenotypes not too dissimilar to wt virus (Table 1).
Complementation groups
The complementation indices of the 25 'new' and 6 'old' ts mutants are shown in Table 2 . The by guest on February 18, 2016 http://femsle.oxfordjournals.org/ Downloaded from 259 data result from three separate determinations for each pairing and show the highest complementation index obtained. Twenty-seven of the 31 mutants appear to comprise at least 24 complementation groups. Mutant tsm5, which was previously undefined (mutant PP 269/38, [13] ), is now categorised into group V along with mutant tsml5. Similarly, mutants tsm3 and tsm6, previously categorised together as complementation group III mutants (PP 242/68 and PP 392/31 [13] ), are now in groups III and V, respectively ( Table 2 ). Mutants tsm7, tsmll, tsml6 and tsm21 could not be assigned to any of these groups since they failed to complement at least two mutants assigned to different complementation groups.
Discussion
Previously, we described six ts mutants derived from wt virus [13] . In the present communication, we describe the isolation and characterisation of a further 25 mutants which, together with the original six mutants, have been classified into 24 complementation groups.
The 31 mutants could be tentatively classified into 5 virulence groups. Seven mutants (tsm2, tsm6, tsml4, tsm18, tsml9, tsm25 and tsm27) have similar virulence to wt (< 10 less virulent) yet tsm27 is unable to plaque at 39°C, tsm2, tsrn6 and tsml4 are unable to plaque at 40°C and tsml8, tsml9 and tsrn25 are 2-20 fold less efficient at plaquing at 40°C than wt. Hence, it is likely that the temperature-sensitive genes of these mutants play little role in MCMV virulence. In contrast, seven mutants (tsm5, tsm9, tsml3, tsm20, tsm22, tsm28 and tsm30) were avirulent for mice and failed to replicate in the salivary glands of mice. Clearly the products of the genes defective in these viruses play a crucial role in replication in vivo and may be involved in cell attachment, entry or other early replication events. Eight mutants were from 12-to 100-fold less virulent than wt, five were 150-to 1500-fold less virulent and four were from 2 000-to 85,000-fold less virulent. These latter mutants should prove interesting since they replicated to high titre in the salivary glands of 1-week-old BALB/c mice (3 x 105 to 5 × 10 7 pfu/ml) yet were not lethal at the highest inoculum available.
Several mutants appeared not to complement each other yet they showed marked differences in temperature-sensitivity profiles and/or virulence. Mutants tsm31 and tsm3 belong to complementation group III but tsm3 does not plaque or replicate at 39°C or 40°C (see [13] ) whereas tsm31 plaques and replicates at both temperatures; the virulence of tsm31 was correspondingly 10-fold greater than that of tsm3 (2 700 pfu/LDs0). Similarly, mutants tsm27 and tsm30 belonging to complementation group XXII differ in that tsm30 failed to infect mice whilst tsm27 not only infected mice but was only six-fold less virulent than the parental wt virus; also they differed in their ability to plaque and replicate at permissive and non-permissive temperatures. Two other mutants (tsm5 and tsml5) are grouped in complementation group V yet they too exhibit differences in plaquing and replication efficiencies although they are both of low virulence. It is possible that if higher titre stocks could be produced that some of these mutants might be found to belong to unique complementation groups.
As for the original six mutants [13] , there was generally little agreement between the shut-off temperature of the mutant and its subsequent virulence. Thus, several mutants failed to plaque at 39°C and although two (tsm9 and tsm28) failed to replicate in mice, one mutant (tsm27) was only 6-fold less virulent than wt virus. Similarly, mutants that failed to plaque at 40°C ranged in virulence from 44 pfu/LDs0 to > 176,000 pfu/LD50.
A comparison of parental virus and ts mutants ranging from < 2-fold up to 85,000-fold difference in virulence may help to elucidate functions or virion components involved in latency, reactivation, immunosuppression, myocarditis and pneumonitis. Studies on the original six mutants have indicated differences in ability to replicate in various tissues following intraperitoneal inoculation and to be reactivated from the latent state; indeed it appears that two mutants could not be reactivated following immunosuppression with anti-thymocyte serum and cyclophosphamide, a procedure which reactivated wt and the other mutants (Furrarah and Sweet, submitted for publication). Similarly, differences in the ability of these mutants to cause pneumonitis in cyclophosphamide-treated mice have been observed (Furrarah and Sweet, submitted for publication). Similar studies on the 25 mutants described in the present communication may prove equally rewarding.
